Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 93
- Registration Number
- NCT00728949
- Locations
- 🇺🇸
ImClone Investigational Site, Nashville, Tennessee, United States
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 109
- Registration Number
- NCT00719966
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2009-06-17
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 70
- Registration Number
- NCT00687648
- Locations
- 🇸🇬
National Cancer Centre - Singapore, Singapore, Singapore
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 396
- Registration Number
- NCT00688194
- Locations
- 🇮🇹
Federico II University Medical School, Naples, Italy
Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT00681928
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 11
- Registration Number
- NCT00661531
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Cooper Cancer Institute, Voorhees, New Jersey, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Breast Cancer Tumor Care Observational Programme
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00660244
- Locations
- 🇦🇹
Research Site, Graz, Austria
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2008-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00638391
Gynecomastia Extension Study
- Conditions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00637182
Second Line Breast Cancer Trial
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 588
- Registration Number
- NCT00635713
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.